CALHM1 Antibody

Product Specifications

Background

CALHM1 Antibody: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP) . The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.

NCBI Gene ID

255022

Swiss Prot

Q8IU99

Accession Number

NP_001001412

Host

Rabbit

Reactivity

Human, Mouse, Rat

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Neuroscience

Purification

CALHM1 Antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1464 - Rat Liver Tissue Lysate

Concentration

1 mg/mL

Buffer

CALHM1 Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

CALHM1 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Fragment

IgG

Symbol

CALHM1

NCBI Official Name

Calcium homeostasis modulator 1

NCBI Organism

Homo sapiens

Background Reference 01

Mattson MP. Pathways towards and away from Alzheimer's disease. Nature2004; 430:631-9.

Background Reference 02

Dreses-Werringloer U, Lambert JC, Vingtdeux V, et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Ab levels, and Alzheimer 's disease risk. Cell2008; 133:1149-61.

Background Reference 03

Nacmias B, Tedde A, Bagnoli S, et al. Lack of implication for CALHM1 P86L common variation in Italian patients with early and late onset Alzheimer 's disease. J. Alzheimers Dis.2010; epub.